SNSS short based on BB and RSIMY OPINION: Jumped into SNSS at this low signal of 4.24. This drop in share price occurred after recent earnings report on March 8th. This is a psychological pitfall, expecting shares to jump back between the middle and bottom Bands by mid week.
THE FACTS:
The company reported $0.21 earnings per share for the quarter
Sunesis Pharmaceuticals has a 52 week low of $1.82 and a 52 week high of $7.69.
Among 5 analysts covering Sunesis Pharmaceuticals, 2 have Buy rating, 1 Sell and 2 Hold.
PHARMA
EYEG Pending BreakoutRelative strength index (RSI-14) for Eyegate Pharmaceuticals, Inc. (EYEG) is at 35.36.
Stock price escalated 6.42% to finalize at $0.58 throughout previous buying and selling session.
EYEG is trading -79.65% downward from the 52-week high mark and 17.24% above from the fifty two-week low mark.
CPHI Win or Fail? (Fib with RSI and Ghost bars)Lets see what next week will bring!
After a recent check, the 14-day RSIfor China Pharma Holdings (CPHI) is currently at 65.41, the 7-day stands at 78.81, and the 3-day is sitting at 94.30.Many professionals agree that realizing a loss is just as important as picking a winner, so I've also included a potential loss area to point out my opinion of when to abort mission. Price Target is anywhere form 0.60 to 0.72 by mid week. The stock has returned 21.95% weekly, which was maintained at 9.59% in the 1-month period. I'm looking forward to the upside of that return!
SRNE on the way UP, bullish to $8.40?SRNE looks bullish.
So far this has been climbing up my original projections, however, exceeding my highest highs as this stock continues to display an extension of wave 3.
IF in fact this current cycle of waves is only a WAVE 3 (per Elliot Wave analysis and rules), then this may reach and exceed the $21.00 mark!
So here are the targets if this count is valid:
Target 1 = $8.40
Target 2 = $13.87
Target 3 = $ 21.00 - $23.50
Veeva Systems: One of my favourite stocks right nowI love it when fundamentals and technicals line up together. I am in general very bullish towards cloud-software companies, thats the future, especially when they have a footing in the pharma industry like veeva. This is a huge market and growing strongly year by year. The chart is a textbook bull flag. I am expecting a move into 80$ over the coming months. Longterm over the coming years we can also see prices above 100$. The only reasonable place to put a stop right now is below 50$. So do your own diligence and research, this is just my opinion towards this stock.
Fundamental analysis by Morgan Stanley:
Veeva Systems Inc
VEEV, a cloud-computing company focused on the pharma and life sciences industry, is an underpriced asset within the broader SaaS universe, according to Morgan Stanley.
The Analyst
Morgan Stanley analyst Stan Zlotsky upgraded Veeva Systems from Equal-weight to Overweight and increased the price target from $69 to $72.
The Thesis
Veeva Systems has durable growth — fueled by an expanding $17-billion total addressable market — and margin potential that is not being reflected in current trading levels, Zlotsky said in a Tuesday note. A conservative setup into 2019 offers scope for estimates and shares to move up, he said.
The company's best-in-class economics are likely to drive longer-term operating margin to 43 percent, representing the highest margin potential in Morgan Stanley's coverage universe, Zlotsky said.
"Veeva's above average sales efficiency and a disciplined go-to-market has enabled the company to simultaneously deliver strong revenue growth and greater than 30-percent operating margins today, well above the 18-percent average among more mature SaaS peers," the analyst said.
Morgan Stanley estimates 16-percent revenue growth on a CAGR basis to $1.7 billion and a 36-percent operating margin by calendar year 2023, resulting in free cash flow of $593 million.
With the 12-percent pullback in Veeva Systems shares since June 2017 compared to a 14-percent gain for the SaaS peer group, Morgan Stanley sees an attractive entry point to rebuild positions in the shares.
NeuroMetrix, Inc, Low Float, Lands Deal With GlaxoSmithKlineNew and innovative product. Quell's proven technology is 5x more powerful on average than other over-the-counter pain relief devices. It is discreet and completely wearable to enable pain relief when your patients need it.
Increased quarterly earnings growth.
Low floater
Resistance at at 3.00 range due to the preferred shares being exercisible at 2.83
Target is 2.50. Nice day trade potential. They just had the biggest trading volume in a very long time, by a long shot.
INSY Target $23 FDA Cannabidiol Fast trackFDA Grants INSYS Therapeutics ‘Fast Track’ Designation for Cannabidiol (CBD) Oral Solution as
INSYS Therapeutics, Inc. (NASDAQ:INSY), announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the company’s cannabidiol (CBD) oral solution for the treatment of Prader-Willi syndrome, a rare and complex genetic disorder characterized by insatiable appetite in children that often leads to obesity and type 2 diabetes.
“FDA’s Fast Track designation will enable an expedited regulatory review process for our proprietary formulation of CBD in the treatment of pediatric patients with Prader-Willi syndrome, a debilitating condition which currently does not have any approved products available,” said Steve Sherman, senior vice president of regulatory affairs for INSYS Therapeutics. “We plan to start the clinical development program for this promising therapy in late first quarter of 2018.”
The most common known genetic cause of life-threatening obesity in children, Prader-Willi syndrome has a prevalence of approximately 1 in 15,000, according to the Prader-Willi Syndrome Association, occurring in males and females equally and in all races.
“We are very encouraged by the FDA’s decision to put CBD for Prader-Willi on the Fast Track and believe it is good news for these young patients, their families and clinicians,” said Saeed Motahari, president and chief executive officer of INSYS Therapeutics. “This special regulatory designation represents a significant milestone in the company’s R&D program, which is focused on developing and delivering safe, effective and novel treatment options using cannabinoids and novel drug delivery technology for unmet medical needs.”
About INSYS
INSYS Therapeutics is a specialty pharmaceutical company that develops and commercializes innovative drugs and novel drug delivery systems of therapeutic molecules that improve patients’ quality of life. Using proprietary spray technology and capabilities to develop pharmaceutical cannabinoids, INSYS is developing a pipeline of products intended to address unmet medical needs and the clinical shortcomings of existing commercial products.
Forward-Looking Statements
This news release contains forward-looking statements including regarding (i) our belief that FDA’s Fast Track designation will enable an expedited regulatory review process for our proprietary formulation of CBD in the treatment of pediatric patients with Prader-Willi syndrome, (ii) our belief that Prader-Willi syndrome currently does not have any approved products available and that our proprietary CBD formulation has potential to be a viable treatment option and (iii) our plan to start the clinical development program for this promising therapy in late first quarter of 2018. These forward-looking statements are based on management’s expectations and assumptions as of the date of this news release; actual results may differ materially from those in these forward-looking statements as a result of various factors, many of which are beyond our control. These factors include, but are not limited to, risk factors described in our filings with the United States Securities and Exchange Commission, including those factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended Dec. 31, 2016 and subsequent updates that may occur in our Quarterly Reports on Form 10-Q. Forward-looking statements speak only as of the date of this news release, and we undertake no obligation to publicly update or revise these statements, except as may be required by law.
DMPI BULL FLAG DMPI (Delmar Pharma) has increased about 40% on a bullish break out. A bull flag has formed after a break out from a large wedge pattern with good volume. Looks like a strong bottom at .80. News was released yesterday that their drug VAL is being "fast tracked" this brings grant money payed by the govt. Looking for a continued bullish trend and news coming from a planned conference in the coming weeks. Bullish and long.
Teva strong resistence at 19.33, yet not a buyDespite the recent company's efforts to reduce its debit, from a technical point of view, I would be neutral with Teva until we will see a cross-over between slow 200d and fast 50d moving average on a daily chart pattern. For those who are aggressives MACD is still positive but keep in mind the resistence at 19.33 first and 20 after. Exhaustion gap betweeen 16 and 18 has been filled. Personally I see such movement as a prize for what the new CEO has done to reduce the impact of debit in short and mid term. Still 2018 will be critical to conferm that what has been undertaken is going toward in the right direction.
VRX imminent attack to 18 dollarsVRX after the correction largly expected, yesterday as demostrated a strong bullish counterattack closing the session slightly less than the short entry recovering mostly 100%. The pattern therefore shows clearly the uptrend line in place. Investors are considering a Q4 better than Q3 looking for new confirmation about debit reduction, so I expect price will move up, breaking down the barrier set at 18 dollars. In case of confirmation this would be a strong signal as Valeant is gaining back attention and potential turn around. Still there is a long way to go through, but what is important right now to highlight is that the trend has been confirmed.
Careful with VRX possible retracementWe reached 17.70 dollars and than a fast pullback as it was for the day before. Important resistence near 18 with possible retracement on the ascendent trendline first and the second dotted trendline after. Personally I sold it at 17 in order to see what it will look like next weeks. RSI overbought, MACD still positive.
Is VRX recharging for a new rally?We have seen in the last few days a dynamic resistance that characterized the pull back of the price from a threshold range between 16.95-16.75. Today the lowest minimum price touched 16.00 dollars (around -2% compare to opening). Violent and prompt reaction with high volatility intraday had set the price at 16.45 +0.3%. 16$ was the point where the ascendant trend line supported the price. Will we see an attack to 17 dollars next days?
$SUNPHARMA Double bottomSUNPHARMA Double bottom now a possibility given sour mood in Pharma space due to DRREDDY issues
This biotech company has something cookingThere is not much time left before there's a big move higher...
Teva Pharmaceutical industries. up or down? This is my first wave chart, so be gentle. :)
i have 2 scenario. One is that wave 5 have ended and we are ready to a correctional wave of A,B,C.
The other is that they will present bad revenue. And the price will continue the down trend, and stop at the support line at 6,49
where the 5th wave could end and start a correction of A,B,C.
Fundamental:
Teva have a great product portfolio, but have lost 64.46% decline year to date. and a 68.83% decline from 30/10/2016 to 30/10/2017
The decline have something to do with there stock pilling on debt that run along the loss in product sales.
The U.S. generics industry is facing significant competitive and pricing pressure, which have been affecting the company’s generic revenues. An increase in FDA generic drug approvals and ongoing customer consolidation are resulting in additional competitive pressure in the industry. earlier this month, in a major blow to Teva, Mylan MYL launched its generic version of the 40 mg formulation, much earlier than expected. Mylan also launched a second generic version of Copaxone 20 mg formulation (once-daily).
Though these generic launches will not hurt Teva’s third-quarter sales and profits, Teva estimates that it will have a negative impact of at least 25 cents per share on fourth-quarter earnings.
Teva Pharmaceutical industries have a P/E Ratio (TTM)=-2,22
And a EPS(TTM)=-6,11
This means that the company is losing money.
besides that, investors now pay 2,22 Dollars less pr earned dollar
They still have a 1,20(8,07%) Forward Dividend and Yield
this means that the company is expecting a low grow rate because of the high yield
(if the Yield is low, a company is expecting high growth expectations and are more likely to give investors reward through out a rise in the stock price)
The Beta is low at 0,72. a Beta below 1 is a less volatile stock.
My target will be at 36.49$
where my stops loss will be at 6,18$
general 1y target estimate from other investors is at 20,02$
Profile:
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams. This segment also develops, manufactures, and sells active pharmaceutical ingredients. The Specialty Medicines segment provides branded specialty medicines for use in central nervous system and respiratory indications, as well as the womens health, oncology, and other specialty businesses. Its products in the central nervous system area comprise Copaxone for multiple sclerosis; Azilect for the treatment of Parkinsons disease; and Nuvigil for the treatment of excessive sleepiness associated with narcolepsy and certain other disorders. This segments products in the respiratory market include ProAir, ProAir Respiclick, QVAR, Duoresp Spiromax, Qnasl, Braltus, Cinqair/Cinqaero, and Aerivio Spiromax for the treatment of asthma and chronic obstructive pulmonary disease, as well as Treanda/Bendeka, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim products in the oncology market. This segment also offers a portfolio of products in the womens health category, which includes ParaGard, Plan B One-Step, and OTC/Rx, as well as other products. The company has collaboration arrangements with Attenukine, Procter & Gamble Company, and Regeneron Pharmaceuticals, Inc.
(source: finance.yahoo.com)
Good luck :)
October 26 Earnings: Gilead - Flying the KiteGilead's core product pipeline, including recent FDA approval is set to soar as key drugs and generics are continuing to outperform.
The company's recent acquisition of KITE Pharma came at the perfect moment with KITE being granted a key drug approval by the FDA.
Gilead's recent cost cutting efforts and R&D focus are to further push growth prospect and boost overall FY guidance.
Generic competition will continue to weigh, however, and limit some blockbuster drug expansion.
I'm starting Gilead with a $90 PT for an extended post-earnings move.
A S/L at $75 around recent area is advised.
October 17 Earnings: Johnson&Johnson- Generic Competition GaloreJohnson & Johnson has been on an impressive intra-quarterly run with solid performance across major segments.
Strengths in the company's performance are to be driven by:
-Imbruvica and Darzalex should continue to perform well. Meaningful improvement from Stelara and Xarelto.
-New product launches like Tremfy (approved in the US late 2017 for plaque psoriasis)
-Revenue contribution from Swiss biotech Actelion, which J&J bought in June.
-Medical devices segment is expected to continue its strong growth trajectory with new product launches.
Weaknesses for the quarter are expected to be:
-Key arthritis drug Remicade to remain under pressure from generic competition.
-Invokana hurting from higher managed care discounting.
-Sluggish FDA review requiring more information before approving new drug treatments.
-Lawsuit from Pfizer to be clarified during the conference call.
Overall, I believe high expenses and generic competition will overcome the positives for the quarter.
I'm starting Johnson&Johnson with a $130 PT for the post earnings move with a tight but flexible 2.5% stop.
Gilead Biotech Aiming HighAlthough the ideas I share with you all revolve around currency pairs, I thought I'd share another specialty of mine: Biotech and pharma stock. If you're in the field, you may have already heard about Gilead having one of the best price to earning ratio of the major biotech companies. You may have also noticed the sharp decline that they experienced in the summer of 2015 which has largely been attributed to a loss in momentum due to the expiration of their patents and increased competition in the market. One could also argue that investors selling their stock contributed to the snowballing drop that seems to still be underway.
Despite all this, there has been a lot of positive news recently with current projects that were once in the pipeline (such as Harvoni and Sovaldi) that have now been approved for the treatment of Hepatitis C. This puts them squarely back in competition with AbbVie and other similarly sized companies. In addition to other projects, the temptation of selling put options on Gilead at this very attractive price should yield dividends within the coming years. That said, the reversal is still not quite there yet but this is a very long term play that you should be ready for.
As with currency pairs, this idea can turn on a dime so you should always take the necessary precautions!
Exactly what we neededVery pleased to see new life being breathed into this stock based on the news today
Article - finance.yahoo.com
Fingers crossed for another big move upward next week.
Gonna be a long weekend, have fun and stay safe
BRISTOL MEYER - US PHARMA STOCK BREAKING OUTBuying dips on BMS Stock. Watch for the 55.20-54.70$ area.
I am targeting for now 60$ and stop should not be placed too far away. 53/52$ seems reasonable to have a nice R:R.
Hourly Chart:
Watch the corrective channel, this might setup a nice long opportunity.
Blessings to you all.
